Stepan Company (SCL)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-30
NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-30
Research Workspace
Put SCL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 35% growth a year, above the roughly 9% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskSCL’s case rests on Project Catalyst savings improving operations as revenue growth accelerates. Revenue growth rose from 2% in Q1 to 15% in Q2 and 17% in Q3. Third-quarter non-GAAP EPS beat consensus, supporting the recent improvement. SCL trades at 27× P/E versus a 17× peer median, despite its own 31× historical multiple. The market is pricing in more growth than our forecast. Management is behind on a stated commitment, and our model puts the next-quarter miss probability near 23%. Peer multiples imply a price about 35% below where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. SCL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering SCL (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare SCL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SCL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 8 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put SCL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Execute Project Catalyst for operational efficiency and cost savings
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Projected savings exceed the 2026 target trajectory and imply substantial recurring 2027 benefits.

Advances: Execute Project Catalyst for operational efficiency and cost savings
Cost savings from Project Catalyst enhance operational efficiency.

Advances: Deliver full year Adjusted EBITDA growth
Margin recovery supports full year Adjusted EBITDA growth.
